pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 23·1 min read
save

Sartorius cuts revenue by €26 million to refund US Trump tariffs to customers

Jul 23, 2026·read at Endpoints ↗RegulatoryNeutral

Sartorius announced a reduction in its revenue by €26 million as it refunds tariffs imposed under the Trump administration to its customers.

The refunds stem from a recent US Supreme Court ruling that blocked certain tariffs, making the company return the charges it had previously passed on.

This is the first time a life-science supplier has disclosed the financial impact of the tariff refunds, highlighting how trade policy changes can affect the sector's earnings.

Sartorius said the adjustment will be reflected in its upcoming financial statements, but it expects the refunds to maintain customer relationships amid ongoing trade uncertainties.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Sartorius reduces revenue by €26M to refund Trump tariffs to customers”

read at Endpoints ↗
82 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sionna Therapeutics, Inc.

related stories

  • Jun 3Mineralys makes money moves before looming hypertension approvalEndpoints
  • Jun 2#ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutEndpoints
  • Jun 2Praxis sinks on late-stage study fail for seizure pill, halts second trialEndpoints
  • May 29#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorEndpoints
  • May 16Makary resigns; Biogen reports Alzheimer’s data; and moreEndpoints